黄斑変性治療の世界市場研究

• 英文タイトル:Market Study on Macular Degeneration Treatment: North America Enjoys Over Two-fifths Market Share

Market Study on Macular Degeneration Treatment: North America Enjoys Over Two-fifths Market Share「黄斑変性治療の世界市場研究」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2301E011
• 出版社/出版日:Persistence Market Research / 2022年10月28日
• レポート形態:英文、PDF、250ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥637,000 (USD4,900)▷ お問い合わせ
  Site Licence¥988,000 (USD7,600)▷ お問い合わせ
  Enterprisewide¥1,378,000 (USD10,600)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Persistence Market Research社の本調査レポートは、世界の黄斑変性治療市場の現状について調査しています。本レポートでは、エグゼクティブサマリー、市場概要、主要市場動向、主要成功要因、市場背景、新型コロナウイルス感染症危機分析、需要分析・予測、治療薬別(抗血管内皮細胞増殖因子製剤、その他)分析、投与経路別(静脈内投与、硝子体内投与、その他)分析、適応疾患別(萎縮型加齢黄斑変性症、滲出型加齢黄斑変性症)分析、エンドユーザー別(病院、眼科クリニック、外来手術センター、その他)分析、地域別(北米、中南米、ヨーロッパ、東アジア、南アジア、オセアニア、中東・アフリカ)分析、構造分析、競争分析、仮定、調査方法などをまとめております。本レポートには、F. Hoffmann-La Roche Ltd.、Novartis AG、Bayer AG、Pfizer Inc.、Bausch Health Companies Inc.、Regeneron Pharmaceuticals Inc.、Amgen Incなどの企業情報が含まれています。
・エグゼクティブサマリー
・市場概要
・主要市場動向
・主要成功要因
・市場背景
・新型コロナウイルス感染症危機分析
・需要分析・予測
・世界の黄斑変性治療市場規模:治療薬別
- 抗血管内皮細胞増殖因子製剤における市場規模
- その他における市場規模
・世界の黄斑変性治療市場規模:投与経路別
- 静脈内投与における市場規模
- 硝子体内投与における市場規模
- その他における市場規模
・世界の黄斑変性治療市場規模:適応疾患別
- 萎縮型加齢黄斑変性症治療の市場規模
- 滲出型加齢黄斑変性症治療の市場規模
・世界の黄斑変性治療市場規模:エンドユーザー別
- 病院における市場規模
- 眼科クリニックにおける市場規模
- 外来手術センターにおける市場規模
- その他における市場規模
・世界の黄斑変性治療市場規模:地域別
- 北米の黄斑変性治療市場規模
- 中南米の黄斑変性治療市場規模
- ヨーロッパの黄斑変性治療市場規模
- 東アジアの黄斑変性治療市場規模
- 南アジアの黄斑変性治療市場規模
- オセアニアの黄斑変性治療市場規模
- 中東・アフリカの黄斑変性治療市場規模
・構造分析
・競争分析
・仮定
・調査方法

Macular Degeneration Treatment Market: Scope of Report

The latest publication by Persistence Market Research on the global macular degeneration treatment market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers in knowing the demand for macular degeneration treatment products and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the macular degeneration treatment market. Shareholders in the macular degeneration treatment market, industry experts, investors, researchers, and reporters, as well as business enthusiasts can leverage insights and information presented in this Persistence Market Research study.

Market statistics, as well as information linked to the macro- as well as macroeconomic variables affecting the business scenario in the macular degeneration treatment market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments

Persistence Market Research’s study on the macular degeneration treatment market offers information divided into five important segments – drug, indication, route of administration, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Drug

Anti-vascular Endothelial Growth Factors
Other
Route of Administration

Intravenous Route
Intravitreal Route
Others
Indication

Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration
End User

Hospitals
Ophthalmology Clinics
Ambulatory Surgical Centers
Others
Region

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa
Key Questions Answered in Report

Which regions will continue to remain the most profitable markets for macular degeneration treatment over the coming years?
How will changing trends influence the market?
How has the COVID-19 crisis influenced market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will affect the market?
How can companies in the macular degeneration treatment market avail themselves the growth opportunities in developed and emerging sectors?
Research Methodology

In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the macular degeneration treatment market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the macular degeneration treatment market more accurate and reliable.

レポート目次

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Development and Innovation Trends

4. Key Success Factors

    4.1. Product Adoption / Usage Analysis

    4.2. Recent Product Launches and Approvals

    4.3. Strategic Promotional Strategies

    4.4. Disease Epidemiology

    4.5. Regulatory and Reimbursement Scenario

    4.6. Product Pipeline Assessment

    4.7. Porters Analysis

    4.8. PESTLE Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Healthcare Outlook

        5.1.3. Per Capita Healthcare Expenditure Outlook

    5.2. Forecast Factors – Relevance & Impact

        5.2.1. Alternative Treatment Market Growth

        5.2.2. Technological Advances

        5.2.3. Development of Novel Products

        5.2.4. Regulatory Imposition

        5.2.5. Product Pipeline

        5.2.6. Per Patient Spending

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID-19 Crisis – Impact Assessment

    6.1. COVID-19 and Impact Analysis

        6.1.1. Revenue By Drug

        6.1.2. Revenue By Route of Administration

        6.1.3. Revenue By Indication

        6.1.4. Revenue By End User

        6.1.5. Revenue By Country

    6.2. 2021 Market Scenario

7. Global Macular Degeneration Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2012–2021 and Forecast, 2022–2032

    7.1. Historical Market Value (US$ Mn) Analysis, 2012–2021

    7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, By Drug

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Drug, 2012–2021

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug, 2022–2032

        8.3.1. Anti-vascular Endothelial Growth Factor

        8.3.2. Other

    8.4. Market Attractiveness Analysis By Drug

9. Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, By Route of Administration

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2021

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2022–2032

        9.3.1. Intravenous Route

        9.3.2. Intravitreal Route

        9.3.3. Others

    9.4. Market Attractiveness Analysis By Route of Administration

10. Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, By Indication

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis By Indication, 2012–2021

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022–2032

        10.3.1. Dry Age-related Macular Degeneration

        10.3.2. Wet Age-related Macular Degeneration

    10.4. Market Attractiveness Analysis By Indication

11. Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, By End User

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis By End User, 2012–2021

    11.3. Current and Future Market Size (US$ Mn) and Forecast By End User, 2022–2032

        11.3.1. Hospitals

        11.3.2. Ophthalmology Clinics

        11.3.3. Ambulatory Surgical Centers

        11.3.4. Others

    11.4. Market Attractiveness Analysis By End User

12. Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, by Region

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Analysis By Region, 2012–2021

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022–2032

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. East Asia

        12.3.5. South Asia

        12.3.6. Oceania

        12.3.7. The Middle East and Africa (MEA)

    12.4. Market Attractiveness Analysis By Region

13. North America Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021

    13.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

        13.3.1. By Country

            13.3.1.1. U.S.

            13.3.1.2. Canada

        13.3.2. By Drug

        13.3.3. By Route of Administration

        13.3.4. By Indication

        13.3.5. By End User

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Drug

        13.4.3. By Route of Administration

        13.4.4. By Indication

        13.4.5. By End User

    13.5. Market Trends

    13.6. Key Market Participants – Intensity Mapping

    13.7. Drivers and Restraints – Impact Analysis

    13.8. Country Level Analysis & Forecast

        13.8.1. U.S. Macular Degeneration Treatment Market Analysis

            13.8.1.1. Introduction

            13.8.1.2. Market Analysis and Forecast by Market Taxonomy

                13.8.1.2.1. By Drug

                13.8.1.2.2. By Route of Administration

                13.8.1.2.3. By Indication

                13.8.1.2.4. By End User

        13.8.2. Canada Macular Degeneration Treatment Market Analysis

            13.8.2.1. Introduction

            13.8.2.2. Market Analysis and Forecast by Market Taxonomy

                13.8.2.2.1. By Drug

                13.8.2.2.2. By Route of Administration

                13.8.2.2.3. By Indication

                13.8.2.2.4. By End User

14. Latin America Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021

    14.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

        14.3.1. By Country

            14.3.1.1. Brazil

            14.3.1.2. Mexico

            14.3.1.3. Argentina

            14.3.1.4. Rest of Latin America

        14.3.2. By Drug

        14.3.3. By Route of Administration

        14.3.4. By Indication

        14.3.5. By End User

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Drug

        14.4.3. By Route of Administration

        14.4.4. By Indication

        14.4.5. By End User

    14.5. Market Trends

    14.6. Key Market Participants – Intensity Mapping

    14.7. Drivers and Restraints – Impact Analysis

    14.8. Country Level Analysis & Forecast

        14.8.1. Brazil Macular Degeneration Treatment Market Analysis

            14.8.1.1. Introduction

            14.8.1.2. Market Analysis and Forecast by Market Taxonomy

                14.8.1.2.1. By Drug

                14.8.1.2.2. By Route of Administration

                14.8.1.2.3. By Indication

                14.8.1.2.4. By End User

        14.8.2. Mexico Macular Degeneration Treatment Market Analysis

            14.8.2.1. Introduction

            14.8.2.2. Market Analysis and Forecast by Market Taxonomy

                14.8.2.2.1. By Drug

                14.8.2.2.2. By Route of Administration

                14.8.2.2.3. By Indication

                14.8.2.2.4. By End User

        14.8.3. Argentina Macular Degeneration Treatment Market Analysis

            14.8.3.1. Introduction

            14.8.3.2. Market Analysis and Forecast by Market Taxonomy

                14.8.3.2.1. By Drug

                14.8.3.2.2. By Route of Administration

                14.8.3.2.3. By Indication

                14.8.3.2.4. By End User

15. Europe Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021

    15.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

        15.3.1. By Country

            15.3.1.1. Germany

            15.3.1.2. Italy

            15.3.1.3. France

            15.3.1.4. U.K.

            15.3.1.5. Spain

            15.3.1.6. BENELUX

            15.3.1.7. Russia

            15.3.1.8. Rest of Europe

        15.3.2. By Drug

        15.3.3. By Route of Administration

        15.3.4. By Indication

        15.3.5. By End User

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Drug

        15.4.3. By Route of Administration

        15.4.4. By Indication

        15.4.5. By End User

    15.5. Market Trends

    15.6. Key Market Participants – Intensity Mapping

    15.7. Drivers and Restraints – Impact Analysis

    15.8. Country Level Analysis & Forecast

        15.8.1. Germany Macular Degeneration Treatment Market Analysis

            15.8.1.1. Introduction

            15.8.1.2. Market Analysis and Forecast by Market Taxonomy

                15.8.1.2.1. By Drug

                15.8.1.2.2. By Route of Administration

                15.8.1.2.3. By Indication

                15.8.1.2.4. By End User

        15.8.2. Italy Macular Degeneration Treatment Market Analysis

            15.8.2.1. Introduction

            15.8.2.2. Market Analysis and Forecast by Market Taxonomy

                15.8.2.2.1. By Drug

                15.8.2.2.2. By Route of Administration

                15.8.2.2.3. By Indication

                15.8.2.2.4. By End User

        15.8.3. France Macular Degeneration Treatment Market Analysis

            15.8.3.1. Introduction

            15.8.3.2. Market Analysis and Forecast by Market Taxonomy

                15.8.3.2.1. By Drug

                15.8.3.2.2. By Route of Administration

                15.8.3.2.3. By Indication

                15.8.3.2.4. By End User

        15.8.4. U.K. Macular Degeneration Treatment Market Analysis

            15.8.4.1. Introduction

            15.8.4.2. Market Analysis and Forecast by Market Taxonomy

                15.8.4.2.1. By Drug

                15.8.4.2.2. By Route of Administration

                15.8.4.2.3. By Indication

                15.8.4.2.4. By End User

        15.8.5. Spain Macular Degeneration Treatment Market Analysis

            15.8.5.1. Introduction

            15.8.5.2. Market Analysis and Forecast by Market Taxonomy

                15.8.5.2.1. By Drug

                15.8.5.2.2. By Route of Administration

                15.8.5.2.3. By Indication

                15.8.5.2.4. By End User

        15.8.6. BENELUX Macular Degeneration Treatment Market Analysis

            15.8.6.1. Introduction

            15.8.6.2. Market Analysis and Forecast by Market Taxonomy

                15.8.6.2.1. By Drug

                15.8.6.2.2. By Route of Administration

                15.8.6.2.3. By Indication

                15.8.6.2.4. By End User

        15.8.7. Russia Macular Degeneration Treatment Market Analysis

            15.8.7.1. Introduction

            15.8.7.2. Market Analysis and Forecast by Market Taxonomy

                15.8.7.2.1. By Drug

                15.8.7.2.2. By Route of Administration

                15.8.7.2.3. By Indication

                15.8.7.2.4. By End User

16. South Asia Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021

    16.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

        16.3.1. By Country

            16.3.1.1. India

            16.3.1.2. Indonesia

            16.3.1.3. Malaysia

            16.3.1.4. Thailand

            16.3.1.5. Rest of South Asia

        16.3.2. By Drug

        16.3.3. By Route of Administration

        16.3.4. By Indication

        16.3.5. By End User

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Drug

        16.4.3. By Route of Administration

        16.4.4. By Indication

        16.4.5. By End User

    16.5. Market Trends

    16.6. Key Market Participants – Intensity Mapping

    16.7. Drivers and Restraints – Impact Analysis

    16.8. Country Level Analysis & Forecast

        16.8.1. India Macular Degeneration Treatment Market Analysis

            16.8.1.1. Introduction

            16.8.1.2. Market Analysis and Forecast by Market Taxonomy

                16.8.1.2.1. By Drug

                16.8.1.2.2. By Route of Administration

                16.8.1.2.3. By Indication

                16.8.1.2.4. By End User

        16.8.2. Indonesia Macular Degeneration Treatment Market Analysis

            16.8.2.1. Introduction

            16.8.2.2. Market Analysis and Forecast by Market Taxonomy

                16.8.2.2.1. By Drug

                16.8.2.2.2. By Route of Administration

                16.8.2.2.3. By Indication

                16.8.2.2.4. By End User

        16.8.3. Malaysia Macular Degeneration Treatment Market Analysis

            16.8.3.1. Introduction

            16.8.3.2. Market Analysis and Forecast by Market Taxonomy

                16.8.3.2.1. By Drug

                16.8.3.2.2. By Route of Administration

                16.8.3.2.3. By Indication

                16.8.3.2.4. By End User

        16.8.4. Thailand Macular Degeneration Treatment Market Analysis

            16.8.4.1. Introduction

            16.8.4.2. Market Analysis and Forecast by Market Taxonomy

                16.8.4.2.1. By Drug

                16.8.4.2.2. By Route of Administration

                16.8.4.2.3. By Indication

                16.8.4.2.4. By End User

17. East Asia Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021

    17.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

        17.3.1. By Country

            17.3.1.1. China

            17.3.1.2. Japan

            17.3.1.3. South Korea

        17.3.2. By Drug

        17.3.3. By Route of Administration

        17.3.4. By Indication

        17.3.5. By End User

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Drug

        17.4.3. By Route of Administration

        17.4.4. By Indication

        17.4.5. By End User

    17.5. Market Trends

    17.6. Key Market Participants – Intensity Mapping

    17.7. Drivers and Restraints – Impact Analysis

    17.8. Country Level Analysis & Forecast

        17.8.1. China Macular Degeneration Treatment Market Analysis

            17.8.1.1. Introduction

            17.8.1.2. Market Analysis and Forecast by Market Taxonomy

                17.8.1.2.1. By Drug

                17.8.1.2.2. By Route of Administration

                17.8.1.2.3. By Indication

                17.8.1.2.4. By End User

        17.8.2. Japan Macular Degeneration Treatment Market Analysis

            17.8.2.1. Introduction

            17.8.2.2. Market Analysis and Forecast by Market Taxonomy

                17.8.2.2.1. By Drug

                17.8.2.2.2. By Route of Administration

                17.8.2.2.3. By Indication

                17.8.2.2.4. By End User

        17.8.3. South Korea Macular Degeneration Treatment Market Analysis

            17.8.3.1. Introduction

            17.8.3.2. Market Analysis and Forecast by Market Taxonomy

                17.8.3.2.1. By Drug

                17.8.3.2.2. By Route of Administration

                17.8.3.2.3. By Indication

                17.8.3.2.4. By End User

18. Oceania Macular Degeneration Treatment Market 2012-2021 and Forecast 2022-2032

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021

    18.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

        18.3.1. By Country

            18.3.1.1. Australia

            18.3.1.2. New Zealand

        18.3.2. By Drug

        18.3.3. By Route of Administration

        18.3.4. By Indication

        18.3.5. By End User

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Drug

        18.4.3. By Route of Administration

        18.4.4. By Indication

        18.4.5. By End User

    18.5. Market Trends

    18.6. Key Market Participants – Intensity Mapping

    18.7. Drivers and Restraints – Impact Analysis

    18.8. Country Level Analysis & Forecast

        18.8.1. Australia Macular Degeneration Treatment Market Analysis

            18.8.1.1. Introduction

            18.8.1.2. Market Analysis and Forecast by Market Taxonomy

                18.8.1.2.1. By Drug

                18.8.1.2.2. By Route of Administration

                18.8.1.2.3. By Indication

                18.8.1.2.4. By End User

        18.8.2. New Zealand Macular Degeneration Treatment Market Analysis

            18.8.2.1. Introduction

            18.8.2.2. Market Analysis and Forecast by Market Taxonomy

                18.8.2.2.1. By Drug

                18.8.2.2.2. By Route of Administration

                18.8.2.2.3. By Indication

                18.8.2.2.4. By End User

19. Middle East and Africa (MEA) Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021

    19.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

        19.3.1. By Country

            19.3.1.1. Turkey

            19.3.1.2. GCC Countries

            19.3.1.3. South Africa

            19.3.1.4. North Africa

            19.3.1.5. Rest of Middle East and Africa

        19.3.2. By Drug

        19.3.3. By Route of Administration

        19.3.4. By Indication

        19.3.5. By End User

    19.4. Market Attractiveness Analysis

        19.4.1. By Country

        19.4.2. By Drug

        19.4.3. By Route of Administration

        19.4.4. By Indication

        19.4.5. By End User

    19.5. Market Trends

    19.6. Key Market Participants – Intensity Mapping

    19.7. Drivers and Restraints – Impact Analysis

    19.8. Country Level Analysis & Forecast

        19.8.1. Turkey Macular Degeneration Treatment Market Analysis

            19.8.1.1. Introduction

            19.8.1.2. Market Analysis and Forecast by Market Taxonomy

                19.8.1.2.1. By Drug

                19.8.1.2.2. By Route of Administration

                19.8.1.2.3. By Indication

                19.8.1.2.4. By End User

        19.8.2. GCC Countries Macular Degeneration Treatment Market Analysis

            19.8.2.1. Introduction

            19.8.2.2. Market Analysis and Forecast by Market Taxonomy

                19.8.2.2.1. By Drug

                19.8.2.2.2. By Route of Administration

                19.8.2.2.3. By Indication

                19.8.2.2.4. By End User

        19.8.3. South Africa Macular Degeneration Treatment Market Analysis

            19.8.3.1. Introduction

            19.8.3.2. Market Analysis and Forecast by Market Taxonomy

                19.8.3.2.1. By Drug

                19.8.3.2.2. By Route of Administration

                19.8.3.2.3. By Indication

                19.8.3.2.4. By End User

        19.8.4. North Africa Macular Degeneration Treatment Market Analysis

            19.8.4.1. Introduction

            19.8.4.2. Market Analysis and Forecast by Market Taxonomy

                19.8.4.2.1. By Drug

                19.8.4.2.2. By Route of Administration

                19.8.4.2.3. By Indication

                19.8.4.2.4. By End User

20. Market Structure Analysis

    20.1. Market Analysis by Tier of Companies

    20.2. Market Share Analysis (%) of Top Players

    20.3. Market Presence Analysis

        20.3.1. By Regional footprint of Players

        20.3.2. Product footprint by Players

        20.3.3. Channel Foot Print by Players

21. Competition Analysis

    21.1. Competition Dashboard

    21.2. Competition Benchmarking

    21.3. Competition Deep Dive (Tentative List)

        21.3.1. F. Hoffmann-La Roche Ltd.

            21.3.1.1. Overview

            21.3.1.2. Product Portfolio

            21.3.1.3. Key Financials

            21.3.1.4. Sales Footprint

            21.3.1.5. SWOT Analysis

            21.3.1.6. Strategy Overview

        21.3.2. Novartis AG

            21.3.2.1. Overview

            21.3.2.2. Product Portfolio

            21.3.2.3. Key Financials

            21.3.2.4. Sales Footprint

            21.3.2.5. SWOT Analysis

            21.3.2.6. Strategy Overview

        21.3.3. Bayer AG

            21.3.3.1. Overview

            21.3.3.2. Product Portfolio

            21.3.3.3. Key Financials

            21.3.3.4. Sales Footprint

            21.3.3.5. SWOT Analysis

            21.3.3.6. Strategy Overview

        21.3.4. Pfizer Inc.

            21.3.4.1. Overview

            21.3.4.2. Product Portfolio

            21.3.4.3. Key Financials

            21.3.4.4. Sales Footprint

            21.3.4.5. SWOT Analysis

            21.3.4.6. Strategy Overview

        21.3.5. Bausch Health Companies Inc.

            21.3.5.1. Overview

            21.3.5.2. Product Portfolio

            21.3.5.3. Key Financials

            21.3.5.4. Sales Footprint

            21.3.5.5. SWOT Analysis

            21.3.5.6. Strategy Overview

        21.3.6. Regeneron Pharmaceuticals Inc.

            21.3.6.1. Overview

            21.3.6.2. Product Portfolio

            21.3.6.3. Key Financials

            21.3.6.4. Sales Footprint

            21.3.6.5. SWOT Analysis

            21.3.6.6. Strategy Overview

        21.3.7. Amgen Inc.

            21.3.7.1. Overview

            21.3.7.2. Product Portfolio

            21.3.7.3. Key Financials

            21.3.7.4. Sales Footprint

            21.3.7.5. SWOT Analysis

            21.3.7.6. Strategy Overview

        21.3.8. Biogen

            21.3.8.1. Overview

            21.3.8.2. Product Portfolio

            21.3.8.3. Key Financials

            21.3.8.4. Sales Footprint

            21.3.8.5. SWOT Analysis

            21.3.8.6. Strategy Overview

        21.3.9. Samsung Bioepis

            21.3.9.1. Overview

            21.3.9.2. Product Portfolio

            21.3.9.3. Key Financials

            21.3.9.4. Sales Footprint

            21.3.9.5. SWOT Analysis

            21.3.9.6. Strategy Overview

        21.3.10. Santen Pharmaceutical Co., Ltd.

            21.3.10.1. Overview

            21.3.10.2. Product Portfolio

            21.3.10.3. Key Financials

            21.3.10.4. Sales Footprint

            21.3.10.5. SWOT Analysis

            21.3.10.6. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology




• 英文レポート名:Market Study on Macular Degeneration Treatment: North America Enjoys Over Two-fifths Market Share
• 日本語訳:黄斑変性治療の世界市場研究
• レポートコード:MRC2301E011お問い合わせ(見積依頼・ご注文・質問)